This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Chinese Academy of Medical Sciences, Shandong Golden Empire Precision Machinery Technology Co., Ltd. Active years: 2016-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2026
Title: Innovations of Guanghui Zheng in Pharmaceutical Chemistry
Introduction
Guanghui Zheng is a notable inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative research and development of compounds with potential therapeutic applications.
Latest Patents
Guanghui Zheng holds a patent for a "Cajanine structure analogous compound, preparation method and use." This patent includes the synthesis method and pharmacological effects of cajanine structure analogous compounds. The compounds described in his patent exhibit various pharmacological activities, including anti-virus properties, nerve protection, and the potential to combat metabolic diseases. Additionally, the patent outlines a total synthesis preparation method for natural products such as cajanine, cajanine A, and cajanine C. This work lays a foundation for future clinical drug development.
Career Highlights
Guanghui Zheng is affiliated with the Chinese Academy of Medical Sciences, where he conducts his research. His work has garnered attention for its innovative approach to drug development and its potential impact on public health.
Collaborations
Guanghui Zheng collaborates with esteemed colleagues, including Zhuorong Li and Xingyue Ji. Their combined expertise enhances the research efforts at the Chinese Academy of Medical Sciences.
Conclusion
Guanghui Zheng's contributions to pharmaceutical chemistry through his innovative patents and research collaborations highlight his role as a significant inventor in the field. His work promises to advance the development of new therapeutic agents in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile